Livzon Pharma (01513) has issued an announcement regarding unusual fluctuations in its A-share trading, as reported by Zhitong Finance APP.

The company's A-shares (stock abbreviation: Livzon Group, stock code: 000513) experienced a cumulative deviation of 20.82% in closing price movements over three consecutive trading days on September 24, September 28, and September 29, 2026. According to relevant regulations of the Shenzhen Stock Exchange, this constitutes an abnormal fluctuation in stock trading.

In response to the unusual trading activity, the company conducted a verification of relevant matters and provided the following explanations regarding circumstances that may affect the abnormal fluctuations:

1. There is no need to correct or supplement information previously disclosed by the company.

2. Regarding recent media reports: The company has not identified any undisclosed material information in recent public media reports that could or has already significantly impacted the company's stock trading price.

3. The company's recent operating conditions are normal, and there have been no significant changes in the internal and external operating environment.

4. Neither the company, its controlling shareholder, nor its actual controller has any undisclosed material matters concerning the company that should be disclosed, nor are there any material matters in the planning stage.

5. During the period of abnormal stock trading fluctuations, neither the controlling shareholder nor the actual controller bought or sold the company's shares.

The company's board of directors confirms that, as of now, there are no matters that should be disclosed but have not been disclosed in accordance with relevant provisions such as the Shenzhen Stock Exchange Stock Listing Rules, nor any related planning, negotiations, intentions, or agreements. The board has also not learned of any information that should be disclosed but has not been disclosed under relevant provisions such as the Shenzhen Stock Exchange Stock Listing Rules, which could significantly affect the trading price of the company's shares and their derivatives. There is no need to correct or supplement information previously disclosed by the company.